The U.S. Food and Drug Administration today approved a drug to help ease the suffering faced by those with certain chronic inflammatory diseases. Arcalyst (rilonacept, an Interleukin-1 blocker) is now approved for the long term treatment of two Cryopyrin-Associated Periodic Syndromes (CAPS) disorders: Familial Cold Auto-Inflammatory Syndrome (FCAS) and Muckle-Wells Syndrome (MWS).
Source:http://www.fda.gov
Discuss Bury
Source:http://www.fda.gov
Discuss Bury
Medinews is an online community dedicated for promoting and discussing latest medical news, research articles and blogs. You can also find regular updates on health news for discussion by health professionals.
Comments